List of Opko Health, Inc. patents

Patents where

Current Assignee

Name

‌

Opko Health, Inc.

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9249144 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds	Patent 9249144 was granted and assigned to Opko Health, Inc. on February, 2016 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9249144	February 2, 2016
‌ US Patent 9469629 NK	Patent 9469629 was granted and assigned to Opko Health, Inc. on October, 2016 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9469629	October 18, 2016
‌ US Patent 7709641 NK1 antagonists	Patent 7709641 was granted and assigned to Opko Health, Inc. on May, 2010 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	7709641	May 4, 2010
‌ US Patent 9688693 NK	Patent 9688693 was granted and assigned to Opko Health, Inc. on June, 2017 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9688693	June 27, 2017
‌ US Patent 7902366 NK	Patent 7902366 was granted and assigned to Opko Health, Inc. on March, 2011 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	7902366	March 8, 2011
‌ US Patent 8470842 Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor	Patent 8470842 was granted and assigned to Opko Health, Inc. on June, 2013 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8470842	June 25, 2013
‌ US Patent 10196394 Hydrochloride salts of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and preparation process therefor	Patent 10196394 was granted and assigned to Opko Health, Inc. on February, 2019 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	10196394	February 5, 2019
‌ US Patent 8178550 Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor	Patent 8178550 was granted and assigned to Opko Health, Inc. on May, 2012 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8178550	May 15, 2012
‌ US Patent 9345692 Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Patent 9345692 was granted and assigned to Opko Health, Inc. on May, 2016 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9345692	May 24, 2016
‌ US Patent 8361500 Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom	Patent 8361500 was granted and assigned to Opko Health, Inc. on January, 2013 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8361500	January 29, 2013
‌ US Patent 9006211 Hypersulfated disaccharide formulations	Patent 9006211 was granted and assigned to Opko Health, Inc. on April, 2015 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9006211	April 14, 2015
‌ US Patent 8796299 NK1 antagonists	Patent 8796299 was granted and assigned to Opko Health, Inc. on August, 2014 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	8796299	August 5, 2014
‌ US Patent 8404702 Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Patent 8404702 was granted and assigned to Opko Health, Inc. on March, 2013 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8404702	March 26, 2013
‌ US Patent 9260428 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds	Patent 9260428 was granted and assigned to Opko Health, Inc. on February, 2016 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9260428	February 16, 2016
‌ US Patent 9101615 Intravenous formulations of neurokinin-1 antagonists	Patent 9101615 was granted and assigned to Opko Health, Inc. on August, 2015 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	9101615	August 11, 2015
‌ US Patent 8754216 NK1 antagonists	Patent 8754216 was granted and assigned to Opko Health, Inc. on June, 2014 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8754216	June 17, 2014
‌ US Patent 9969711 NK	Patent 9969711 was granted and assigned to Opko Health, Inc. on May, 2018 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9969711	May 15, 2018
‌ US Patent 9822116 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds	Patent 9822116 was granted and assigned to Opko Health, Inc. on November, 2017 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	9822116	November 21, 2017
‌ US Patent 8273895 NK	Patent 8273895 was granted and assigned to Opko Health, Inc. on September, 2012 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8273895	September 25, 2012
‌ US Patent 8026364 NK	Patent 8026364 was granted and assigned to Opko Health, Inc. on September, 2011 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8026364	September 27, 2011
‌ US Patent 10000493 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds	Patent 10000493 was granted and assigned to Opko Health, Inc. on June, 2018 by the United States Patent and Trademark Office.	‌ Opko Health, Inc.	‌ Opko Health, Inc.	United States Patent and Trademark Office	10000493	June 19, 2018
‌ US Patent 7981905 Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Patent 7981905 was granted and assigned to Opko Health, Inc. on July, 2011 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	7981905	July 19, 2011
‌ US Patent 8552191 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds			‌ Opko Health, Inc.	United States Patent and Trademark Office	8552191	October 8, 2013
‌ US Patent 8546351 Hypersulfated disaccharide formulations	Patent 8546351 was granted and assigned to Opko Health, Inc. on October, 2013 by the United States Patent and Trademark Office.		‌ Opko Health, Inc.	United States Patent and Trademark Office	8546351	October 1, 2013

24 results

0 selected

24 results

0 selected